News

Filter

Current filters:

Anti-viralsAtripla

1 to 9 of 16 results

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

Study on generic HIV drugs prompts AHF to demand Gilead cuts ARV prices

16-01-2013

A new study published in the Annals of Internal Medicine that provides a snapshot of a simplified cost/benefit…

Anti-viralsAtriplaGenericsGilead SciencesNorth AmericaPharmaceuticalPricingStribild

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Gilead's Stribild to reinforce HIV/AIDS revenues as key patents expire

06-11-2012

US biotech firm Gilead Science's (Nasdaq: GILD) combination drug Stribild (elvitegravir 150mg/cobicistat…

Anti-viralsAtriplaBiotechnologyBristol-Myers SquibbGilead SciencesMarkets & MarketingPatentsReyatazStribildSustiva

1 to 9 of 16 results

COMPANY SPOTLIGHT

Menarini

Back to top